Cancer Genetics
癌症遗传学
基本信息
- 批准号:8300271
- 负责人:
- 金额:$ 30.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-01 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAcute Lymphocytic LeukemiaAdrenal Gland CancerAppointmentBRCA1 geneBase Excision RepairsBase SequenceBasic ScienceBeerBeliefBioinformaticsBiological AssayBiometryBreastCDX2 geneCancer Center Support GrantCancer PatientCellular biologyChromatinChromosome Fragile SitesClinical ManagementClinical SciencesCollaborationsColonColon CarcinomaColonic NeoplasmsCommitComplexDNA DamageDNA RepairDefectDevelopmentEZH2 geneEnhancersEpigenetic ProcessErinaceidaeFacultyFamilyFundingGene ExpressionGene Expression ProfileGene Expression RegulationGene FusionGene MutationGene SilencingGenesGeneticGenetic ProgrammingGenetic TranscriptionGenetically Engineered MouseGenomeGenome StabilityGenomic InstabilityGenomicsGerm LinesGlioblastomaGoalsGonadal Steroid HormonesGrantHead and neck structureHumanInterdisciplinary StudyKnock-outKnockout MiceKnowledgeLaboratory ResearchLeadLymphomaMAP Kinase GeneMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of esophagusMalignant neoplasm of lungMalignant neoplasm of ovaryMalignant neoplasm of prostateMalignant neoplasm of thyroidMentorsMethodologyMethodsMethyltransferaseModelingMolecularMolecular AnalysisMutationNatureNeoplasm MetastasisNeurofibromatosesNonhomologous DNA End JoiningNormal CellNuclear ProteinPathogenesisPathway interactionsPopulation SciencesPreventionProcessProstateProteinsProteomicsPublicationsRadiationRecordsRecurrenceRegulationResearchResearch PersonnelRetrotranspositionRobin birdRoleSchoolsScienceScreening for cancerSomatic CellSomatic MutationSteroid ReceptorsStudy modelsSystemTechnologyTherapeuticTherapeutic InterventionTissuesTranscriptional RegulationTransgenic MiceTransgenic OrganismsTranslational ResearchTumor Suppressor GenesUniversity of Michigan Comprehensive Cancer CenterVariantViralartemisbasebeta catenincancer cellcancer geneticschromatin modificationcollegegene repressiongenetic analysishistone acetyltransferaseimprovedmalignant breast neoplasmmelanomamembermouse modelnerve stem cellnotch proteinnovel diagnosticsoncologyoutcome forecastovarian neoplasmprofessorprogramsprotein functionreceptor functionrepairedresponsestem cell fatetraittranscription factortumorigenesis
项目摘要
The Cancer Genetics Program (CGP) is an interdisciplinary research group of 37 investigators from 13 departments and three different schools/colleges, Since the past funding cycle, tine research base of the Cancer Genetics Program has increased 180% from $3,866,370 to $10,978,820 total annual direct support, of which $1,132,859 is from the NCI. Over this last grant period, there were 472 publications of Cancer Genetics Program members, of which 8.4% are intra-programmatic and 31.9% are Inter-programmatic. The CGP pursues laboratory and translational research, emphasizing genetic and genomics approaches, with the overarching goal of advancing knowledge of the nature and role of mutations and gene expression changes In the development and altered phenotypic traits of cancer. Investigatory in the CGP are committed to the pursuit of research that will not only inform understanding of the origins and nature of cancer but that will also lead to novel diagnostic approaches for cancer and improved clinical management of cancer patients. Investigators in the Program collaborate with investigators in other University of Michigan Comprehensive Cancer Center (UMCCC) programs in the Basic Science, Clinical Science and Population Sciences Divisions, including Cancer Cell Biology, Radiation Sciences, Experimental Therapeutics, Breast Oncology, GI Oncology, Prostate Oncology, and Biomedical Prevention. The CGP has four major research themes:
I) Defining oncogene and tumor suppressor gene network defects and gene expression signatures in cancers of various types.
II) Characterization of mechanisms of gene regulation by transcription factor complexes and chromatin modification factors in cancer cells.
III) Elucidation of genetic and epigenetic mechanisms contributing to genomic instability in cancer.
IV) Development of genetically engineered mouse models for investigating the role of recurrent gene defects in cancer pathogenesis.
癌症遗传学计划(CGP)是一个跨学科的研究小组,由来自13个部门和三个不同的学校/学院的37名研究人员组成,自上一个资助周期以来,癌症遗传学计划的研究基础已经从3,866,370美元增加到10,978,820美元,其中1,132,859美元来自NCI。在上一个资助期内,癌症遗传学项目成员发表了472篇论文,其中8.4%是项目内的,31.9%是项目间的。CGP追求实验室和转化研究,强调遗传和基因组学方法,其总体目标是推进对突变和基因表达变化在癌症发展和改变表型特征中的性质和作用的认识。CGP的研究致力于研究,不仅有助于了解癌症的起源和性质,而且还将导致癌症的新诊断方法和改善癌症患者的临床管理。该计划的研究人员与密歇根大学综合癌症中心(UMCCC)基础科学,临床科学和人口科学部门的其他计划的研究人员合作,包括癌细胞生物学,放射科学,实验治疗学,乳腺肿瘤学,GI肿瘤学,前列腺肿瘤学和生物医学预防。CGP有四个主要研究主题:
I)定义各种类型癌症中的癌基因和肿瘤抑制基因网络缺陷和基因表达特征。
II)癌细胞中转录因子复合物和染色质修饰因子的基因调控机制的表征。
III)阐明导致癌症中基因组不稳定性的遗传和表观遗传机制。
IV)开发用于研究复发性基因缺陷在癌症发病机制中的作用的基因工程小鼠模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAX S. WICHA其他文献
MAX S. WICHA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAX S. WICHA', 18)}}的其他基金
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 30.17万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 30.17万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 30.17万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 30.17万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 30.17万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 30.17万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 30.17万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 30.17万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别: